Alkem Laboratories Approves Unaudited Financial Results for Quarter Ended Sep 30, 2025
Alkem Laboratories Limited approved the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2025 in its board meeting held on 13th November, 2025.
The announcement provides information about the company's financial performance, which is relevant to investors and can influence stock prices.
The announcement is a factual disclosure of financial results, without indications of strong positive or negative outlook.
* Alkem Laboratories Limited approved the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2025 in its board meeting held on 13th November, 2025. * The meeting commenced at 11.40 a.m. and concluded at 01.30 p.m. * Consolidated revenue from operations stood at ₹40,009.9 million for the quarter ended September 30, 2025, and ₹73,721.3 million for the six months ended September 30, 2025. * Standalone revenue from operations was ₹25,420.3 million for the quarter and ₹49,142.0 million for the six months ended September 30, 2025. * Exceptional items for the half year ended 30 September 2025 primarily includes gain of ₹142.9 million from the sale of Indore facility classified as held for sale in the previous year and sold in the quarter ended 30 June 2025.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.